Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
In Reply: We appreciate the clarifications
from Drs Meyerhoff and Murphy. The accompanying corrections clarify the status
of FDA approval for specific medication indications and adjust the Working
Group's recommended doses for 3 drugs used in the treatment or postexposure
prophylaxis of anthrax. Although these corrections do not substantively change
any of the key Working Group recommendations, they are important enough to
warrant specific notice.
Meyerhoff and Murphy emphasize that ciprofloxacin has been approved
by the FDA for both children and adults for postexposure prophylaxis for inhalational
anthrax. They also state that the FDA has not approved any therapy specifically
for the treatment of inhalational anthrax while "penicillin G procaine and
doxycycline are both approved by the FDA for the treatment of disease due
to B anthracis, as well as for anthrax PEP. Ciprofloxacin
is only approved for "inhalational anthrax (postexposure)" and is not approved
by the FDA for the treatment of inhalational anthrax." At this time, then,
clinicians have no options that have been approved by the FDA for the treatment
of inhalational anthrax. In the absence of FDA approval for any specific treatment
for inhalational anthrax, clinicians must rely on other sources of guidance
regarding treatment recommendations for this disease process.
Inglesby T, O'Toole T. Guidelines for Treatment of Anthrax—Reply. JAMA. 2002;288(15):1848-1849. doi:10.1001/jama.288.15.1845